Harmony Biosciences to acquire Main Line’s Zynerba in up to $200M deal


The centerpiece of Harmony Biosciences' deal is Zynerba's lead new drug candidate Zygel, a pharmaceutically produced transdermal cannabinoid therapy.

Previous Tampa's HCI Group requests 75K Citizens policies after reporting more profits
Next M&A Due Diligence